Navigation Links
Brain Cell Repair Loss disclosed

According to researchers at the University of Stanford, have discovered the point of no return stage at which adult brain cells lose the ability to repair themselves. The investigators said their work should help find new opportunities to reverse this regeneration loss and speed nerve cell growth.

Researcher Ben Barres, a Stanford neurobiologist, felt that they can study any disease that causes// the brain and spinal cord to degenerate multiple sclerosis, spinal cord injury, stroke, the list goes on and on. Thereby provides grounds for optimism that we can come up with new treatments for patients.

Nerve cells, or neurons, first grow by sprouting long "branches" called axons. The cells then switch gears and begin budding many small "twigs" called dendrites that reach out all around them. These long and short branches are what neurons use to talk with one another. Since axons are longer than dendrites, most nerve damage from injury or disease involve axons. Although neurons in the arms and legs can regenerate axons incredibly efficiently, the ones in the brain and spinal cord the central nervous system lose the ability early in development.

Previously, medical scientists thought nerve cell surroundings released streams of growth-stifling proteins that kept neurons from repairing themselves. "A lot of evidence suggests this is true," Barres said. "But we wondered, 'Is that all? Are there other problems? What about the neurons themselves?'"

Barres and lead researcher Jeff Goldberg discovered a neuron's failure to regenerate also may be due to its own internal programming. Once nerve cells start growing dendrites, they apparently cannot switch back. The investigators took lab-grown nerve cells from the retinas of rat embryos and newborns and compared growth rates. Surprising, but even if the cells from newborn rats were given a host of growth-enhancing biochemicals, the embryonic rat cell axons grew about 10 times faster, spro
'"/>




Page: 1 2

Related medicine news :

1. Use of Cellular Phones associated with Increased risk of Brain Tumors
2. Brain death – How to cope with it
3. “Brain fingerprinting”- The new lie detectr
4. Nasal Spray Could Take Drugs Direct to Brain.
5. Virus Combats Brain Tumour
6. Nasal Spray Could Take Drugs Directly to Brain
7. Control of anger disorder connected to Brain Dysfunction
8. High Levels of Protein Linked to Brain Shrinkage
9. Brain damage affects artistic skill
10. Brain cells protected by new compounds
11. Brain changes observed in people with sleep apnoea
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Brain Cell Repair Loss disclosed

(Date:5/21/2013)... CA (PRWEB) May 21, 2013 DISCcert ... materials showing how to use 17 DISC applications at ... is a natural progression. , The July 25 & ... the top 17 ways of applying DISC. The time-tested, ... certified graduates. The user-friendly DISC training materials ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... to protecting the rights of victims injured by defective ... Journal of Bone & Joint Surgery on May 15, ... can be used to identify complications that occur in ... any symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...
(Date:5/21/2013)... The Orsiro stent, which is a novel stent ... non-inferiority to the Xience Prime everolimus-eluting stent for ... loss at nine months in the results of ... , The BIOFLOW-II substudy used intravascular ultrasound (IVUS) ... neointimal hyperplasia and stent apposition at nine months ...
(Date:5/21/2013)... Hillsboro, OR (PRWEB) May 21, 2013 ... curing systems at the 20th Annual IMI European ... As a proven market leader, Phoseon continues to invest ... while accelerating the adoption of UV LED curing in ... of product families on the market offering both air ...
(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...
Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2
... The Lancet Supports Cardio-Protective Potential of Aleglitazar - , ... will start Phase III clinical investigations for aleglitazar, its innovative ... morbidity and mortality in high risk patients with type 2 ... II SYNCHRONY study published today in The Lancet(1) ...
... , Customizable Survival Kit Offers One Stop for ... Local Healthcare Market Drivers and Health Plan Trends ... a leading provider of managed care market intelligence, ... shifts in membership at the state level than ...
... the company that will become public from the planned ... today filed a second amendment to its Form 10 ... that includes information about its post-spin board of directors ... under a consent decree for its Alaris(R) infusion products. ...
... United Spinal Association ( www.UnitedSpinal.org ) presents the ... ) , the region,s premiere lifestyle-enhancing Expo designed to ... aging Americans. , , The Independence Expo will ... at the Suffolk Community College Sports & Exhibition Complex in ...
... PSI-7851 was generally safe and well tolerated in Phase 1a ... results from single ascending and multiple ascending dose trials are ... June 9 Pharmasset, Inc. (Nasdaq: VRUS ) ... study and begun dosing in a multiple ascending dose trial ...
... ... its Multilayer Aneurysm Repair System (MARS) has received CE Mark approval for treating patients ... ... announced today that it has received CE Mark approval for the commercial sale of ...
Cached Medicine News:Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 2Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 3Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 4Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 5Health News:Commercial Pharmacy Benefit Enrollment Experiencing Greater Shifts in Florida than Commercial Medical Benefit Enrollment 2Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 2Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 3Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 4Health News:United Spinal Association Presents The 2009 Independence Expo: Improving Life for the Disabled and the Aging 2Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 2Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 3Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 4Health News:Cardiatis Multilayer Aneurysm Repair System, MARS, Receives CE Mark Approval for Treating Peripheral Aneurysms 2
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May ... SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... published online the positive Phase 2a study results of ... is an investigational monoclonal antibody targeting the alpha subunit ... signaling of both IL-4 and IL-13, drivers of Th2 ...
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...
(Date:5/21/2013)... NEW YORK , May 21, 2013 ... market research report is available in its ... Changing Regulatory and Reimbursement Scenario for Medical ... http://www.reportlinker.com/p01188015/Changing-Regulatory-and-Reimbursement-Scenario-for-Medical-Devices-in-the-US-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging   ... Devices in the US Market ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... prioritization -, LOUISVILLE, Colo., Dec. 10 ... announced an operational restructuring to align,critical resources ... partner for Replidyne,s late-stage antibiotic, faropenem,medoxomil (faropenem), ... exploring additional corporate development opportunities., The ...
... outcomes for premature babies, FORT WORTH, Texas, ... Now, they are helping improve the care of,premature ... care unit recently implemented the use of the ... results in decreasing the,incidence of chronic lung disease ...
Cached Medicine Technology:Replidyne Provides Strategic Update 2Replidyne Provides Strategic Update 3Replidyne Provides Strategic Update 4Replidyne Provides Strategic Update 5Replidyne Provides Strategic Update 6Harris Methodist Fort Worth Hospital Using Bubbles to Help Babies Breathe 2
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • Not available with casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Medicine Products: